Iraj Hosseini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iraj Hosseini has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Christine Moussion
Genentech, South San Francisco, California
2 shared publications - Jérémie Decalf
Department of Cancer Immunology, Genentech Inc., South San Francisco, CA, 94080, USA
2 shared publications Saroja Ramanujan
Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080
2 shared publicationsShomyseh Sanjabi
Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080
2 shared publications- Travis W. Bainbridge
Genentech
2 shared publications Ahmad Ebtikar
Department of Analytical and Quality Control, Genentech Inc., South San Francisco, CA, 94080, USA
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 214, 107303
A quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15
- 30 September 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 214, 107303
Open AccessA quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15
- Open Access
- 5 July 2025
- Published by Elsevier in EBioMedicine
- Vol. 118, 105822
Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations
- 5 July 2025
- Published by Elsevier in EBioMedicine
- Vol. 118, 105822
Open AccessEffectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations
- Open Access
- 15 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 660
A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.
- 15 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 660
Open AccessA Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.
- Open Access
- 4 January 2018
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 45 (2) , 259-275
gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug development
Modeling and simulation (M&S) is increasingly used in drug development to characterize pharmacokinetic-pharmacodynamic (PKPD) relationships and support various efforts such as target feasibility assessment, molecule selection, human PK projection, and preclinical and clinical dose and schedule determination. While model development typically require mathematical modeling expertise, model exploration and simulations could in many cases be performed by scientists in various disciplines to support the design, analysis and interpretation of experimental studies. To this end, we have developed a versatile graphical user interface (GUI) application to enable easy use of any model constructed in SimBiology® to execute various common PKPD analyses. The MATLAB®-based GUI application, called gPKPDSim, has a single screen interface and provides functionalities including simulation, data fitting (parameter estimation), population simulation (exploring the impact of parameter variability on the outputs of interest), and non-compartmental PK analysis. Further, gPKPDSim is a user-friendly tool with capabilities including interactive visualization, exporting of results and generation of presentation-ready figures. gPKPDSim was designed primarily for use in preclinical and translational drug development, although broader applications exist. gPKPDSim is a MATLAB®-based open-source application and is publicly available to download from MATLAB® Central™. We illustrate the use and features of gPKPDSim using multiple PKPD models to demonstrate the wide applications of this tool in pharmaceutical sciences. Overall, gPKPDSim provides an integrated, multi-purpose user-friendly GUI application to enable efficient use of PKPD models by scientists from various disciplines, regardless of their modeling expertise.
- 4 January 2018
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 45 (2) , 259-275
Open AccessgPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug development
Modeling and simulation (M&S) is increasingly used in drug development to characterize pharmacokinetic-pharmacodynamic (PKPD) relationships and support various efforts such as target feasibility assessment, molecule selection, human PK projection, and preclinical and clinical dose and schedule determination. While model development typically require mathematical modeling expertise, model exploration and simulations could in many cases be performed by scientists in various disciplines to support the design, analysis and interpretation of experimental studies. To this end, we have developed a versatile graphical user interface (GUI) application to enable easy use of any model constructed in SimBiology® to execute various common PKPD analyses. The MATLAB®-based GUI application, called gPKPDSim, has a single screen interface and provides functionalities including simulation, data fitting (parameter estimation), population simulation (exploring the impact of parameter variability on the outputs of interest), and non-compartmental PK analysis. Further, gPKPDSim is a user-friendly tool with capabilities including interactive visualization, exporting of results and generation of presentation-ready figures. gPKPDSim was designed primarily for use in preclinical and translational drug development, although broader applications exist. gPKPDSim is a MATLAB®-based open-source application and is publicly available to download from MATLAB® Central™. We illustrate the use and features of gPKPDSim using multiple PKPD models to demonstrate the wide applications of this tool in pharmaceutical sciences. Overall, gPKPDSim provides an integrated, multi-purpose user-friendly GUI application to enable efficient use of PKPD models by scientists from various disciplines, regardless of their modeling expertise.